Tamoxifen in treatment of intraductal breast cancer: National surgical adjuvant breast and bowel project B-24 randomised controlled trial

Lancet

Volumn 353, Issue 9169, 1999, Pages 1993-2000

  Fisher, Bernard ^a   Dignam, James ^b   Wolmark, Norman ^d   Wickerham, D Lawrence ^d   Fisher, Edwin R ^e   Mamounas, Eleftherios ^f   Smith, Roy ^a   Begovic, Mirsada ^c   Dimitrov, Nikolay V ^g   Margolese, Richard G ^h   Kardinal, Carl G ⁱ   Kavanah, Maureen T ^j   Fehrenbacher, Louis ^k   Oishi, Robert H ^l  

^a NSABP Foundation Inc   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d ALLEGHENY GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^f Mount Sinai Center for Breast Health   (United States)

^g MICHIGAN STATE UNIVERSITY   (United States)

^h MCGILL UNIVERSITY   (Canada)

ⁱ OCHSNER MEDICAL CENTER   (United States)

^j BOSTON MEDICAL CENTER   (United States)

^k KAISER PERMANENTE   (United States)

^l UNIVERSITY OF HAWAII   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AFFECTIVE NEUROSIS; ARTICLE; BREAST CANCER; CANCER INVASION; CLINICAL TRIAL; COMEDO; CONTROLLED CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; ENDOMETRIUM CANCER; FEMALE; FLUID RETENTION; FOLLOW UP; HOT FLUSH; HUMAN; INTRADUCTAL CARCINOMA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MENSTRUATION DISORDER; NECROSIS; PARTIAL MASTECTOMY; PHLEBITIS; PRIORITY JOURNAL; PROBABILITY; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOEMBOLISM; VAGINA DISCHARGE;

EID: 0033549344     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)05036-9     Document Type: Article

References (26)

1. Rosner D., Bedwani R.N., Vana J., Baker H.W., Murphy G.P. Noninvasive breast carcinoma: results of a national survey by the American College of Surgeons. Ann Surg. 192:1980;139-147.
2. Lagios M.D., Westdahl P.R., Margolin F.R., Rose M.R. Duct carcinoma in situ: relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures. Cancer. 50:1982;1309-1314.
3. Ernster V.L., Barclay J., Kerlikowske K.et al. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA. 275:1996;913-918.
4. Fisher B., Bauer M., Margolese R.et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 312:1985;665-673.
5. Fisher B., Costantino J., Redmond C.et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med. 328:1993;1581-1586.
6. Fisher B., Dignam J., Wolmark N.et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 16:1998;441-452.
7. Jordan V.C. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer. 12:1976;419-424.
8. Jordan V.C., Allen K.E. Evaluation of the antitumour activity of the nonsteroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer. 16:1980;239-251.
9. Fisher B., Costantino J., Redmond C.et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 320:1989;479-484.
10. Fisher B., Redmond C. New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent. J Natl Cancer Inst. 83:1991;1278-1280.
11. Fisher B., Costantino J.P., Wickerham D.L.et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 90:1998;1371-1388.
12. Fisher B., Wolmark N., Fisher E.R., Deutsch M. Lumpectomy and axillary dissection for breast cancer: surgical, pathological, and radiation considerations. World J Surg. 9:1985;692-698.
13. Prentice R.L., Kalbfleisch J.D., Peterson A.V., Flournoy N., Farewell V.T., Breslow N.E. The analysis of failure times in the presence of competing risks. Biometrics. 34:1978;541-554.
14. Gaynor J.J., Feuer E.J., Tan C.C.et al. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc. 88:1993;400-409.
15. Fleming T.R., Harrington D.P., O'Brien P.C. Designs for group sequential tests. Controlled Clin Trials. 5:1984;348-361.
16. Fisher E.R., Costantino J., Fisher B., Palekar A.S., Redmond C., Mamounas E. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-17: intraductal carcinoma (duct carcinoma in situ). Cancer. 115:1995;1310-1319.
17. Fisher E.R. Pathobiological considerations relating to the treatment of intraductal carcinoma (ductal carcinoma in situ) of the breast. CA Cancer J Clin. 47:1997;52-64.
18. Fisher E.R., Dignam J., Tan Chiu E.et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of protocol B-17. Cancer. 1999;. in press.
19. Giri D.D., Dundas S.A., Nottingham J.F., Underwood J.C. Oestrogen receptors in benign epithelial lesions and intraductal carcinomas of the breast: an immunohistological study. Histopathology. 15:1989;575-584.
20. Barnes R., Masood S. Potential value of hormone receptor assay in carcinoma in situ of breast. Am J Clin Pathol. 94:1990;533-537.
21. Zafrani B., Leroyer A., Fourquet A.et al. Mammographically detected ductal in situ carcinoma of the breast analyzed with a new classification: a study of 127 cases: correlation with estrogen and progesterone receptors, P53 and c-erb B-2 proteins, and proliferative activity. Semin Diagn Pathol. 11:1994;208-214.
22. Allred D.C., Berardo M.D., Prosser J., O'Connell P. Biologic and genetic features of in-situ breast cancer. Silverstein M. Ductal carcinoma in situ of the breast. 1997;37-49 Williams and Wilkins, Baltimore.
23. Pallis L., Wilking N., Cedermark B., Rutqvist L.E., Skoog L. Receptors for estrogen and progesterone in breast carcinoma in situ. Anticancer Res. 12:1992;2113-2115.
24. Berardo M., Hilsenbeck S.G., Allred D.C. Histological grading of noninvasive breast cancer and its relationship to biological features. Lab Invest. 74:1996;15A. abstr 68.
25. Leal C.B., Schmitt F.C., Bento M.J., Maia N.C., Lopes C.S. Ductal carcinoma in situ of the breast: histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erb B-2 protein. Cancer. 75:1995;2123-2131.
26. Recht A., Rutgers E.J.Th., Fentiman I.S., Kurtz J.M., Mansel R.E., Sloane J.P. The Fourth EORTC DCIS Consensus Meeting (Château Marquette, Heemskerk, The Netherlands, 23-24 January 1998) Conference Report. Eur J Cancer. 34:1998;1664-1669.